Cargando…
Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates
AIM: Surgery is an important therapeutic option for Crohn's disease. The need for first bowel surgery seems to have decreased with the introduction of tumour necrosis factor inhibitors (TNFi; adalimumab or infliximab). However, the impact of TNFi on the need for intestinal surgery in Crohn'...
Autores principales: | Eberhardson, Michael, Myrelid, Pär, Söderling, Jonas K., Ekbom, Anders, Everhov, Åsa H., Hedin, Charlotte R. H., Neovius, Martin, Ludvigsson, Jonas F., Olén, Ola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306633/ https://www.ncbi.nlm.nih.gov/pubmed/34905282 http://dx.doi.org/10.1111/codi.16021 |
Ejemplares similares
-
Probability of Stoma in Incident Patients With Crohn’s Disease in Sweden 2003-2019: A Population-based Study
por: Everhov, Åsa H, et al.
Publicado: (2021) -
Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn’s Disease: A Population-Based Cohort Study
por: Everhov, Åsa H, et al.
Publicado: (2020) -
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023) -
Validating surgical procedure codes for inflammatory bowel disease in the Swedish National Patient Register
por: Forss, Anders, et al.
Publicado: (2019) -
Earnings during adulthood in patients with childhood‐onset inflammatory bowel disease: a nationwide population‐based cohort study
por: Malmborg, Petter, et al.
Publicado: (2022)